Overview of metformin: special focus on metformin extended release

Bibliography

• Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2010;2:1
   Google Scholar
• Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007;35(10):1956-62
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol 1994;112(2):671-5
   PubMed Web of Science ®Google Scholar
• Gusler G, Gorsline J, Levy G, Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol 2001;41(6):655-61
   PubMed Web of Science ®Google Scholar
• Hou SY, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carrier Syst 2003;20(6):459-97
   PubMed Web of Science ®Google Scholar
• Hilgendorf C, Ahlin G, Seithel A, Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007;35(8):1333-40
   PubMed Web of Science ®Google Scholar
• Kennedy M, Chinwah P, Wade DN. A pharmacological method of measuring mouth caecal transit time in man. Br J Clin Pharmacol 1979;8(4):372-3
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Levy G. Pharmacokinetics in clinical practice. I. concepts. JAMA 1976;235(17):1864-7
   PubMed Web of Science ®Google Scholar
• Tucker GT, Casey C, Phillips PJ, Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12(2):235-46
   PubMed Web of Science ®Google Scholar
• Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005;44(7):721-9
   PubMed Web of Science ®Google Scholar
• Hong Y, Rohatagi S, Habtemariam B, Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol 2008;48(6):696-707
   PubMed Web of Science ®Google Scholar
• Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979;16(3):195-202
   PubMed Web of Science ®Google Scholar
• Rothman DL, Magnusson I, Katz LD, Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 1991;254(5031):573-6
   PubMed Web of Science ®Google Scholar
• Staehr P, Hother-Nielsen O, Beck-Nielsen H, Hepatic autoregulation: response of glucose production and gluconeogenesis to increased glycogenolysis. Am J Physiol Endocrinol Metab 2007;292(5):E1265-9
   PubMed Web of Science ®Google Scholar
• Roden M, Bernroider E. Hepatic glucose metabolism in humans–its role in health and disease. Best Pract Res Clin Endocrinol Metab 2003;17(3):365-83
   PubMed Web of Science ®Google Scholar
• Krssak M, Brehm A, Bernroider E, Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 2004;53(12):3048-56
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117(5):1422-31
   PubMed Web of Science ®Google Scholar
• Van Leeuwen N, Nijpels G, Dekker JM, The effect of genetic variation in OCT1, OCT2 and MATE1 on metformin treatment response. Diabetes 2011;60:A387
   Web of Science ®Google Scholar
• Wang Z-, Yin OQP, Tomlinson B, Chow MSS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008;18(7):637-45
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Vormfelde SV, Balen D, The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86(3):299-306
   PubMed Web of Science ®Google Scholar
• Argaud D, Roth H, Wiernsperger N, Leverve XM. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur J Biochem 1993;213(3):1341-8
   PubMedGoogle Scholar
• Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin. synergism with insulin. Biochem Pharmacol 1988;37(22):4353-8
   PubMed Web of Science ®Google Scholar
• Hardie DG. Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 2011;93(4):891S-16
   PubMed Web of Science ®Google Scholar
• Zheng D, MacLean PS, Pohnert SC, Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol 2001;91(3):1073-8
   PubMed Web of Science ®Google Scholar
• Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005;307(5708):384-7
   PubMed Web of Science ®Google Scholar
• El-Mir MY, Nogueira V, Fontaine E, Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275(1):223-8
   PubMed Web of Science ®Google Scholar
• Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348(Pt 3):607-14
   PubMed Web of Science ®Google Scholar
• Foretz M, Hebrard S, Leclerc J, Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120(7):2355-69
   PubMed Web of Science ®Google Scholar
• Zhou K, Bellenguez C, Spencer CCA, Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;43(2):117-20
   PubMed Web of Science ®Google Scholar
• Mulherin AJ, Oh AH, Kim H, Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011;152(12):4610-19
   PubMed Web of Science ®Google Scholar
• Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-(alpha) in mice. Diabetologia 2011;54(2):339-4
   PubMed Web of Science ®Google Scholar
• Natali A, Baldeweg S, Toschi E, Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27(6):1349-57
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Bonomo K, Trovati M. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010;8(3):327-3
   PubMed Web of Science ®Google Scholar
• Standeven KF, Ariens RA, Whitaker P, The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002;51(1):189-97
   PubMed Web of Science ®Google Scholar
• Chakrabarti R, Hocking ED, Fearnley GR. Fibrinolytic effect of metformin in coronary-artery disease. Lancet 1965;2(7406):256-9
   PubMed Web of Science ®Google Scholar
• Janka HU. Platelet and endothelial function tests during metformin treatment in diabetes mellitus (short communication). Horm Metab Res Suppl 1985;15:120-2
   PubMedGoogle Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK prospective diabetes study (UKPDS) group. JAMA 1999;281(21):2005-12
   PubMed Web of Science ®Google Scholar
• UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-65
   PubMed Web of Science ®Google Scholar
• UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-65
   PubMed Web of Science ®Google Scholar
• Goldstein BJ. Clinical translation of "a diabetes outcome progression trial": ADOPT appropriate combination oral therapies in type 2 diabetes. J Clin Endocrinol Metab 2007;92(4):1226-8
   PubMed Web of Science ®Google Scholar
• Garber AJ, Duncan TG, Goodman AM, Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103(6):491-7
   PubMed Web of Science ®Google Scholar
• Fujioka K, Brazg RL, Raz I, Efficacy, dose-response relationship and safety of once-daily extended-release metformin (glucophage(registered trademark) XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: Results from two double-blind, placebo-controlled studies. Diabetes Obes Metab 2005;7(1):28-39
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
   PubMed Web of Science ®Google Scholar
• Belsey J, Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes Obes Metab 2008;10 Suppl 1:1-7
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ortiz M, Martinez-Abundis E, Ramos Zavala MG, Combination of metformin extended release and glimepiride in a single dosage in type 2 diabetic patients with monotherapy failure: clinical trial of efficacy and safety. J Diabetes 2011;3:268
   Google Scholar
• Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006;3(3):159-65
   PubMedGoogle Scholar
• Linnebjerg H, Kothare PA, Skrivanek Z, Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes. Diabet Med 2006;23(3):240-5
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30(8):1979-87
   PubMed Web of Science ®Google Scholar
• Stenlof K, Raz I, Neutel J, Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin 2010;26(10):2355-63
   PubMed Web of Science ®Google Scholar
• Jadzinsky M, Pfutzner A, Paz-Pacheco E, Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11(6):611-22
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Charpentier G, Ostgren CJ, Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26(7):540-9
   PubMed Web of Science ®Google Scholar
• UK prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-53
   PubMed Web of Science ®Google Scholar
• The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86
   PubMed Web of Science ®Google Scholar
• Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab 2003;29(1):79-81
   PubMed Web of Science ®Google Scholar
• Florez H, Luo J, Castillo-Florez S, Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med 2010;122(2):112-20
   PubMed Web of Science ®Google Scholar
• Schwartz S, Fonseca V, Berner B, Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006;29(4):759-64
   PubMed Web of Science ®Google Scholar
• Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther 2003;25(2):515-29
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. the multicenter metformin study group. N Engl J Med 1995;333(9):541-9
   PubMed Web of Science ®Google Scholar
• Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49(5):721-49
   PubMed Web of Science ®Google Scholar
• Hermann LS, Schersten B, Bitzen P-, Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994;17(10):1100-9
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73(6):1294-301
   PubMed Web of Science ®Google Scholar
• Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16(4):621-9
   PubMed Web of Science ®Google Scholar
• Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004;6(2):133-56
   PubMed Web of Science ®Google Scholar
• Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008;99(6):995-1000
   PubMed Web of Science ®Google Scholar
• Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003;29(4 Pt 2):6S44-52
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Rautio K, Ruokonen A, Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88(10):4649-54
   PubMed Web of Science ®Google Scholar
• Lund SS, Tarnow L, Stehouwer CD, Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008;158(5):631-4
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84(5):489-97
   PubMed Web of Science ®Google Scholar
• Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114(6):597-605
   PubMed Web of Science ®Google Scholar
• Ruggiero-Lopez D, Lecomte M, Moinet G, Reaction of metformin with dicarbonyl compounds. possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 1999;58(11):1765-73
   PubMed Web of Science ®Google Scholar
• Piga R, Naito Y, Kokura S, Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis 2007;193(2):328-34
   PubMed Web of Science ®Google Scholar
• Quagliaro L, Piconi L, Assaloni R, Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005;183(2):259-67
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Sera Y, Abe Y, Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 2004;64(3):225-8
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254-8
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330(7503):1304-5
   PubMed Web of Science ®Google Scholar
• Libby G, Donnelly LA, Donnan PT, New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32(9):1620-5
   PubMed Web of Science ®Google Scholar
• Landman GW, Kleefstra N, van Hateren KJ, Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33(2):322-6
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia 2008;51(8):1552-3
   PubMed Web of Science ®Google Scholar
• Dandona P, Fonseca V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. Diabetes Care 1983;6(5):472-4
   PubMed Web of Science ®Google Scholar
• Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 1998;15(8):651-6
   PubMed Web of Science ®Google Scholar
• Tomkin GH. Malabsorption of vitamin B12 in diabetic patients treated with phenformin: a comparison with metformin. Br Med J 1973;3(5882):673-5
   PubMedGoogle Scholar
• Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010;33(1):156-61
   PubMed Web of Science ®Google Scholar
• Ting RZ-, Szeto CC, Chan MH-, Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;166(18):1975-9
   PubMedGoogle Scholar
• Stumvoll M, Nurjhan N, Perriello G, Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333(9):550-4
   PubMed Web of Science ®Google Scholar
• Brown JB, Pedula K, Barzilay J, Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21(10):1659-63
   PubMed Web of Science ®Google Scholar
• Assan R, Heuclin C, Ganeval D, Metformin-induced lactic acidosis in the presence of acute renal failure. Diabetologia 1977;13(3):211-17
   PubMed Web of Science ®Google Scholar
• Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia 1978;14(2):75-87
   PubMed Web of Science ®Google Scholar